Drugs & Aging

, Volume 22, Issue 8, pp 709–715 | Cite as

Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy

  • Arti Hurria
  • Kelly Brogan
  • Katherine S. Partageas
  • Ann Jakubowski
  • Marjorie Zauderer
  • Carol Pearce
  • Larry Norton
  • Jane Howard
  • Clifford Hudis
Original Research Article



To determine the association between changes in complete blood counts and grade 3 or 4 toxicities from cycle 1 to cycle 2 during adjuvant chemotherapy in women ≥65 years of age with breast cancer.

Design and methods

A retrospective review was performed on 1405 patients ≥65 years of age who were treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. From this cohort, we identified patients with stage I–II breast cancer who received adjuvant chemotherapy: cyclophosphamide, methotrexate and fluorouracil (CMF) or the anthracycline-based regimens doxorubicin and cyclophosphamide (AC) or AC followed by paclitaxel (AC-T). Patients were excluded from the analysis if they had a prior history of breast cancer or chemotherapy, or if they had no baseline blood counts available for review. Toxicities, dose modification and causality were recorded.


The 104 patients who met our criteria had received either CMF (n = 58; mean age 70.6 years, range 65–78) or an anthracycline-based regimen (n = 46; mean age 68.9 years, range 65–77). Of these patients, 50% experienced treatment delay or treatment-related grade 3 or 4 toxicity. A decrease in white blood cell count and absolute neutrophil count from cycle 1 to cycle 2 was associated with grade 3 or 4 haematological toxicity, febrile neutropenia, hospitalisation and initiation of filgrastim for secondary prophylaxis. A decrease in haemoglobin was associated with febrile neutropenia and hospitalisation. Advanced age was not associated with a significant change in complete blood counts, other than a decline in absolute neutrophil count in patients receiving CMF.


In this cohort of older patients who received chemotherapy for breast cancer, changes in blood counts from cycle 1 to cycle 2 were associated with increased risk of treatment-related grade 3 or 4 toxicity.


  1. 1.
    Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005; 55(1): 10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80(7): 1273–83PubMedCrossRefGoogle Scholar
  3. 3.
    Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85(19): 1580–4PubMedCrossRefGoogle Scholar
  4. 4.
    Busch E, Kemeny M, Fremgen A, et al. Patterns of breast cancer care in the elderly. Cancer 1996; 78(1): 101–11PubMedCrossRefGoogle Scholar
  5. 5.
    Bergman L, Dekker G, van Leeuwen FE, et al. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 1991; 67(9): 2227–34PubMedCrossRefGoogle Scholar
  6. 6.
    Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156(1): 85–90PubMedCrossRefGoogle Scholar
  7. 7.
    Yancik R, Ries LG, Yates JW. Breast cancer in aging women: a population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63(5): 976–81PubMedCrossRefGoogle Scholar
  8. 8.
    Hillner BE, Penberthy L, Desch CE, et al. Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat 1996; 40(1): 75–86PubMedCrossRefGoogle Scholar
  9. 9.
    Ballard-Barbash R, Potosky AL, Harlan LC, et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88(11): 716–26PubMedCrossRefGoogle Scholar
  10. 10.
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002; 20(24): 4636–42PubMedCrossRefGoogle Scholar
  11. 11.
    Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol 2003; 46(2): 121–6PubMedCrossRefGoogle Scholar
  12. 12.
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341(27): 2061–7PubMedCrossRefGoogle Scholar
  13. 13.
    Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer [published erratum appears in J Clin Oncol 2004; 22 (23): 4811]. J Clin Oncol 2003; 21(12): 2268–75PubMedCrossRefGoogle Scholar
  14. 14.
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5(3): 224–37PubMedCrossRefGoogle Scholar
  15. 15.
    Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000; 14(1): 193–212, x-xiPubMedCrossRefGoogle Scholar
  16. 16.
    Repetto L, Carreca I, Maraninchi D, et al. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003; 45(2): 123–8PubMedCrossRefGoogle Scholar
  17. 17.
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRefGoogle Scholar
  18. 18.
    Silber JH, Fridman M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998; 16(7): 2392–400PubMedGoogle Scholar
  19. 19.
    Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18(6): 521–9PubMedCrossRefGoogle Scholar
  20. 20.
    Balducci L, Lyman GH. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001; 19(5): 1583–5PubMedGoogle Scholar
  21. 21.
    Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J Clin Oncol 1998; 16(6): 2065–9PubMedGoogle Scholar
  22. 22.
    Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force Guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003, 72Google Scholar
  23. 23.
    Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18(20): 3558–85PubMedGoogle Scholar
  24. 24.
    Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332(14): 901–6PubMedCrossRefGoogle Scholar
  25. 25.
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [published erratum appears in J Clin Oncol 2003; 21 (11): 2226]. J Clin Oncol 2003; 21(8): 1431–9PubMedCrossRefGoogle Scholar
  26. 26.
    Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999; 281(18): 1714–7PubMedCrossRefGoogle Scholar
  27. 27.
    Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 2000; 14(11A): 221–7Google Scholar
  28. 28.
    Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4(8): 459–60PubMedCrossRefGoogle Scholar
  29. 29.
    Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40(15): 2201–16PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Arti Hurria
    • 1
  • Kelly Brogan
    • 1
  • Katherine S. Partageas
    • 1
  • Ann Jakubowski
    • 1
  • Marjorie Zauderer
    • 1
  • Carol Pearce
    • 1
  • Larry Norton
    • 1
  • Jane Howard
    • 1
  • Clifford Hudis
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations